CORAL GABLES, Fla. Allergan and Stiefel Laboratories have entered into an agreement to develop, manufacture, distribute, and promote dermatological products containing tazarotene, the active ingredient in Tazorac.
Tazorac is used to treat psoriasis and acne in a gel and cream form. Under the agreement, Stiefel will use its U.S. sales force to co-promote Allergan’s Tazorac to dermatologists. The company will also utilize the drug in several different ways to bring unique therapeutic options to the market as well as use Allergan’s proprietary technology.
“This is a great opportunity,” said Bill Humphries, chief commercial officer at Stiefel Laboratories. “Tazorac will provide the perfect complement to our acne portfolio, which also includes Duac, and it will allow Stiefel to offer best-in-class topical acne treatments to our customers. Given our long-standing and well-established presence in the dermatology arena, we will be able make an immediate and important impact with Tazorac.”